A randomized, double-blind, placebo-controlled cross-over study of epicutaneous immunotherapy for food allergy.

A randomized, double-blind, placebo-controlled cross-over study of epicutaneous immunotherapy for food allergy. - Epicutaneous immunotherapy for food allergy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033049

Enrollment

Registered

2018-06-19

Start date

2011-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

egg allergy allergen phase egg allergy placebo phase milk allergy allergen phase milk allergy placebo phase

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: children with food Allergy

Exclusion criteria

Exclusion criteria: children without food Allergy

Design outcomes

Primary

Measure	Time frame
The effects of epicutaneous immunotherapy were evaluated according to the cumulative tolerated dose in an oral food challenge.	—

Countries

Japan

Contacts

Public ContactKoichi Yamaguchi

Hachioji Hospital, Faculty of Medicine, Tokai University Department of Pediatrics

yamaguchi@douai.jp042-639-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026